Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Adaptimmune Therapeutics plc (ADAP) ADS

Sell:$3.93 Buy:$3.95 Change: $0.28 (7.61%)
NASDAQ:1.43%
Market closed |  Prices as at close on 28 January 2020 | Switch to live prices |
Sell:$3.93
Buy:$3.95
Change: $0.28 (7.61%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 28 January 2020 | Switch to live prices |
Sell:$3.93
Buy:$3.95
Change: $0.28 (7.61%)
Market closed |  Prices as at close on 28 January 2020 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.

Contact details

Address:
60 Jubilee Avenue
ABINGDON
OX14 4RX
United Kingdom
Telephone:
+44 (1235) 430000
Website:
https://www.adaptimmune.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ADAP
ISIN:
US00653A1079
Market cap:
$497.54 million
Shares in issue:
630.95 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Adrian Rawcliffe
    Chief Executive Officer, Director
  • Michael Garone
    Interim Chief Financial Officer
  • William Bertrand
    Chief Operating Officer
  • Elliot Norry
    Senior Vice President, Chief Medical Officer
  • John Lunger
    Chief Patient Supply Officer
  • Helen Tayton-Martin
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.